BIGGER IS BETTER
Trissel’sÔ 2 Clinical Pharmaceutics Database is the largest compilation of clinical pharmaceutics information ever assembled.
Trissel’sÔ
2 continues to grow and now includes the information from over 4970 studies and references. Nearly 60,200 parenteral drug compatibility
results are presented along with drug information on more than 700 parenteral drugs and solutions and
stability information on compounded non-parenteral formulations for 460 drugs. This is more than FIVE
TIMES the number of research results of other standard reference
sources – print or electronic.
Trissel’sÔ
2 is not just more comprehensive, it is also timelier. The database already
includes information that will not appear in print resources for months or
years as well as a wealth of data only available in Trissel’sÔ
2. Just some of the new information recently incorporated into Trissel’sÔ
2 includes:
1. Idarubicin
HCl compatibility with parenteral narcotics and other controlled drugs
2. Sunitinib
stability prepared for oral administration
3. Stability
and compatibility of palonosetron HCl with propofol
4. Compatibility
of idarubicin HCl with other injectable drugs
5. Extended
stability of methyl nicotinate solution
6. Stability
of calcitriol in syringes
7. Stability
and compatibility of ketamine and propofol mixtures
8. Compatibility
of parenteral beta-lactam anti-infective drugs with idarubicin HCl
9. Tobramycin
and ceftazidime stability in Icodextrin peritoneal dialysis solution
10. Nefopam
HCl incompatibility in admixtures with several proton pump inhibitors
11. Daptomycin
extended stability in normal saline
12. Pantoprazole
sodium instability in a parenteral nutrition admixture
13. Temocillin
stability and compatibility with 47 other drugs
14. Compatibility
of common parenteral anti-infective medications with idarubicin HCl
15. Stability
of miconazole oral gel
16. Extended
stability of selected drugs packaged in syringes
17. Ketoprofen,
nefopam, and acetaminophen injection compatibility and stability
18. Compatibility
of common parenteral drugs with idarubicin HCl
19,
20. Stability of ketamine-morphine
admixtures (2 studies)
21. Compatibility
of idarubicin HCl with selected parenteral medications
22. Busulfan
stability in normal saline
23. Cytarabine
extended stability in dextrose 5%
24. Curcumin
2% topical gels formulation, activity, and stability
25. Effect
of various factors on fenbendazole suspension
26. Stability
of thiamine in an oral liquid formulation
27. Idarubicin
HCl compatibility with other selected antineoplastic drugs
28. Itraconazole
stability in infusion solutions
29. Absence
of light effects on ketamine HCl solution
30. Dissolution
stability differences among oral cefadroxil formulations
31.
Diclofenac sodium 75-mg/mL injection stability
32.
Anidulafungin compatibility with several antineoplastic drugs
33. Stability
of levalbuterol HCl mixed with ipratropium bromide inhalation
34.
Stability of two-drug mixtures of parenteral analgesics
35.
Compatibility of selected oncology drugs with anidulafungin
36.
Formoterol fumarate compatibility with four other inhalation drugs
37.
Phenylephrine HCl extended stability in D5W and NS
38.
Anidulafungin compatibility with various parenteral medications
39.
Captopril stability at pH 3 in aqueous solution
40.
Decomposition of thiamine and ascorbate sodium in powders due to deliquescence
41.
Colistimethate sodium inhalation solution extended stability
42.
Compatibility of various parenteral drugs with anidulafungin
43.
Stability and compatibility of three-drug pain admixtures in an implantable
pump
44.
Stability of chloroquine phosphate topical gels
45.
Bupivacaine plus sufentanil extended stability packaged in syringes
46.
Anidulafungin compatibility with selected parenteral medications
47.
Stability of cefminox sodium in peritoneal dialysis solution
48. Sodium
folinate extended stability during frozen and refrigerated storage
49.
Lidocaine, dexamethasone, and epinephrine stability in an EMDA solution
50.
Anidulafungin compatibility with common parenteral drugs
51.
Clonidine HCl injection extended stability
52.
Compatibility of various controlled parenteral drugs with anidulafungin
53. Colistin
conversion in colistimethate sodium i.v. infusions
54.
Stability and compatibility of levalbuterol with several other inhalation drugs
55.
Stability of two venlafaxine formulations for enteral feeding tube
administration
56.
Compatibility of anidulafungin with selected other anti-infective drugs
57.
Doripenem extended solution stability
58.
Stability of quinidine sulfate oral liquid
59. Atenolol
injection compatibility with selected other parenteral medications
60,
61. The acidic
and basic properties of proton pump inhibitors (2 studies)
62.
Stability of ethanol-free phenobarbital oral liquids
63.
Daptomycin use in peritoneal dialysis solutions
64.
Incompatibility of amiodarone and heparin
65. Some
factors influencing ziconotide acetate stability in implantable pumps
66.
Compatibility of atenolol injection with selected controlled drugs
67.
Stability of rifampin oral suspension
68.
Stability of verapamil HCl oral solution
69. Extended
stability of magnesium sulfate in Intravia containers
70.
Moxifloxacin incompatibility with furosemide
71.
Voriconazole solution long-term stability
72.
Stability and compatibility of ornidazole with 18 other drugs
73. Succinylcholine
chloride injection stability at room temperature
74. Cefepime
HCl stability and compatibility with selected drugs and solutions
75.
Compatibility of penicillin and cephalosporin antibiotics with atenolol
injection
76. Sodium
hypochlorite topical solution stability
77.
Verapamil hydrochloride oral suspension stability
78.
Chloramphenicol eye drops instability in tropical heat
79.
Compatibility of atenolol injection with selected anti-infective drugs
80.
Cefuroxime stability with five other drugs
81.
Daptomycin incompatibility with vancomycin hydrochloride
82.
Ciprofloxacin incompatibility with magnesium 2+ ions
83.
Incompatibility of dicloxacillin injection with magnesium sulfate
84. Atenolol
compatibility with common cancer drugs
85. Stability
of ondansetron HCl oral suspension
86. pH effects on the stability of capreomycin sulfate injection
87.
Stability of 23 medications under ambulance storage conditions
88.
Gatifloxacin aqueous solubility at various pH values
89. Extended
stability of a four-drug analgesic combination over 26 days
90.
Compatibility of atenolol with selected antineoplastic medications
91. Rifampin
solubility and stability
92.
Stability and compatibility of three cephalosporin antibiotics in invert sugar
5%
93.
Stability of fortified atropine sulfate injection for use in treating nerve
agent attack
94. Morphine
sulfate suppositories stability
95.
Stability of pravastatin during enteral administration
96.
Stability of thalidomide as an extemporaneous injection
97.
Mechlorethamine HCl stability in six topical formulations
98. Atenolol
compatibility with selected parenteral drugs
99.
Stability of piroxicam cream
100.
Incompatibility of omeprazole and ascorbic acid injection
101. Codeine
stability in an oral liquid preparation
102.
Parenteral drug compatibility studies with atenolol
103.
Stability of progesterone suppositories
104.
Solubility of ethionamide
105. Ethambutol dissociation and solubility information
106.
Triprolidine HCl stability in an oral syrup formulation
107. The
compatibility of atenolol and common parenteral medications
108.
Stability of mebendazole oral suspension formulation
109.
Ophthalmic ketotifen fumarate; stability of 8 formulations
110.
Stability of thalidomide as an oral liquid
111.
Stability of isoproterenol HCl compound elixir
112.
Metronidazole compatibility with a number of common parenteral medications
113.
Bendamustine HCl stability in Dextrose 2.5% and Sodium Chloride 0.45%
114.
Incompatibility of dornase alfa inhalation with gentamicin sulfate
115. Fospropofol disodium compatibility with drugs and solutions
116.
Ketamine HCl extended stability in normal saline
117.
Indomethacin topical gel stability
118.
Stability of labetalol oral suspension
119.
Extended stability of atropine sulfate in normal saline
120.
Compatibility of selected controlled drugs with metronidazole infusion
121.
Stability of panitumumab in sodium chloride 0.9%
122.
Ketoconazole oral suspension stability
123.
Stability of metoprolol tartrate oral liquids
124.
Extended stability of emetine HCl injection
125.
Influence of pH on the stability of interferon alfa
126.
Thioridazine solubility and pKa
127.
Extended stability of metronidazole benzoate oral suspension
128.
Compatibility of selected beta-lactam antibiotics with metronidazole infusion
129.
Ganciclovir stability in two oral liquids
130.
Compatibility of several drugs with enteral feeding
131.
Metolazone stability in oral liquid preparations
132.
Extended stability of ziconotide with morphine at varying concentrations
133.
Alprostadil stability in sodium chloride 0.9%
134.
Stability of three cephalosporins in fructose 5% infusion solution
135.
Metronidazole compatibility with several common anti-infective drugs
136. Stability
of hydralazine HCl oral solution
137.
Compatibility and stability of gatifloxacin admixed with etamsylate in D5W and
NS
138.
Stability and solubility of cycloserine
139.
Compatibility and stability of risedronate sodium mixed with food thickeners
140.
Photosensitivity of amlodipine besylate
141. Ceftobioprole medocaril compatibility with
calcium-containing drugs/solutions
142.
Metronidazole infusion compatibility with other parenteral drugs
143.
Baclofen oral suspension stability
144.
Stability of two captopril oral liquids
145.
Curcumin stability in a transdermal film
146.
Dolasetron mesylate stability in two oral liquids
147. Zinc
chloride stability injection stability
148.
Stability of ciprofloxacin ophthalmic gel
149.
Precipitation of floxacillin infusion
150.
Metronidazole compatibility with common parenteral medications
151.
Stability of two diltiazem hydrochloride oral liquids
152.
Flucytosine stability in an oral liquid preparation
153.
Latanoprost ophthalmic solution efficacy after elevated temperature storage
154.
Cefazolin sodium stability in two ophthalmic solutions
155.
Stability of pegaspargase in infusion solutions
156.
Stability of tetracycline and nadifloxacin ointments mixed together
157.
Metronidazole compatibility with selected antineoplastic medications
158,
159. Leucovorin
and levoleucovorin incompatibility with fluorouracil (2 studies)
160.
Vancomycin hydrochloride ophthalmic solution long-term stability
161.
Orphenadrine citrate injection stability
162. Manganese
chloride injection stability
163.
Albuterol sulfate stability with excipients
164.
Enalapril maleate stability in a transdermal film
165.
Compatibility of selected parenteral drugs with metronidazole infusion
166.
Stability of two bethanechol chloride oral liquids
167.
Clonazepam oral suspension stability
168.
Stability of a topical T-A-C solution
169.
Stability of dipyridamole suspension
170.
Pegfilgrastim storage and stability
171.
pH-stability of aqueous dicloxacillin sodium
172. Sodium
ferric gluconate complex compatibility with NS and TPNs
173. Sodium
phenylacetate and sodium benzoate compatibility with dextrose 10% and arginine
HCl 10%
174.
Nesiritide compatibility with common drugs given by injection or infusion
175.
Stability of acetazolamide oral liquid
176.
Parecoxib sodium stability in various diluents
177.
Rasburicase stability in normal saline
178.
Stability of carnitine and coenzyme Q10 oral solution
179.
Compatibility of selected parenteral medications with nesiritide injection in
D5W
180.
Ifosfamide stability in infusion solutions in different containers
181.
Stability of allopurinol oral liquid
182.
Stability of bimatoprost and latanoprost ophthalmic solutions during in-use
conditions
183.
Nesiritide compatibility with narcotics and other controlled drugs
184.
Stability of alprazolam oral liquid
185.
Omeprazole compatibility with mannitol
186.
Compatibility of calcium and phosphate salts
187.
Piroxicam and dexpanthenol topical gel stability
188.
Compatibility of nesiritide with beta-lactam antibiotics
189.
Stability of atenolol oral liquid
190.
Dexrazoxane stability in normal saline
191.
Acetaminophen stability in a solution for rectal administration
192.
Ketoprofen 2% topical solution stability
193. Compatibility
of selected anti-infective parenteral drugs with nesiritide in D5W
194.
Minocycline HCl topical gel stability
195.
Stability of azathioprine oral liquid
196. Effects
of increasing temperature and humidity on aztreonam
197.
Stability of flurandrenolide topical film
198.
Stability of dichlorobenzyl alcohol 1% dental gel
199.
Nesiritide compatibility with several anti-infective medications
200.
Tromethamine injection stability
201.
Metronidazole and cefmenoxime HCl compatibility (3 studies)
202.
Stability of estradiol 0.1% vaginal solution
203.
Nesiritide compatibility with common parenteral medications
204.
Clevidipine butyrate compatibility with various solutions
205.
Carboplatin extended stability in dextrose 5%
206.
Acyclovir and entecavir stability in oral liquids
207.
Basiliximab stability in infusion solutions
208. Drug
release from compounded prednisolone suppositories
209.
Stability of extemporaneously-compounded propafenone oral liquid
210.
Compatibility of selected injectable medications with nesiritide
211.
Ibuprofen lysine incompatibility with parenteral nutrition
212. Retinol
in topical cream stability under simulated-use conditions
213.
Pentetate calcium trisodium stability in infusion solutions
214.
Nesiritide Y-site compatibility with other parenteral drugs
215.
Paclitaxel protein-bound stability in normal saline
216. Benzoyl
peroxide stability in various solvent systems as liquids and gels
217.
Compatibility of nesiritide with selected antineoplastic drugs
218. Indomethacin
stability in injections solubilized with several hydrotropes
219.
Amoxicillin and clavulanate increased decomposition when frozen
220.
Artesunate rectal gel formulation and extended stability
221. The
compatibility of several symptomatic and supportive care drugs with nesiritide
222.
Lidocaine and epinephrine stability when buffered with sodium bicarbonate
223. Vitamin
C and E stability in topical microemulsion formulations
224.
Nesiritide compatibility with various cancer treatment medications
225.
Dihydroergotamine mesylate stability and compatibility
226.
Alteplase stability during ultrasound exposure
227.
Fluorescein stability and compatibility
228.
Ifosfamide compatibility with common injections
229. Iron
sucrose compatibility in normal saline
230.
Fluconazole physical and chemical stability
231.
Compatibility of ifosfamide with common parenteral drugs
232.
Sincalide stability in sodium chloride 0.9%
233.
Potential incompatibility between captopril and magnesium stearate
234. Ifosfamide
compatibility with selected parenteral medications
235.
Stability of a lidocaine-tetracaine eutectic mixture anesthetic (EMLA)
cream
236.
Antimicrobial efficacy of parabens after dilution
237. The
compatibility of common parenteral drugs with ifosfamide
238. Iron
sucrose compatibility in two TPN solutions
239.
Morphine sulfate stability in Instillagel
240.
Hydroxocobalamin compatibility with drugs and solutions
241.
Indinavir sulfate thermal stability
242.
Ifosfamide compatibility with parenteral controlled drugs
243.
Alglucosidase alfa solution compatibility and stability
244.
Physical and chemical stability of phenobarbital sodium oral liquid
245.
Tretinoin and isotretinoin photodegradation
246.
Compatibility of selected beta-lactam antibiotics with ifosfamide
247.
Comparison of dexamethasone and prednisolone liquid formulations
248.
Alkaline pH effects on atenolol and propranolol
249.
Cefuroxime axetil stability after reconstitution
250.
Compatibility of ifosfamide with selected anti-infective drugs
251.
Norepinephrine bitartrate extended stability in infusion solutions
252.
Stability and compatibility of piperacillin/tazobactam with selected drugs and
solutions
253.
Ifosfamide compatibility with selected antibiotics and other anti-infective
drugs
254.
Octreotide acetate compatibility with various parenteral drugs
255.
Stability of three cephalosporin antibiotics in xylitol 5%
256.
Dalteparin stability diluted in sodium chloride 0.9%
257.
Triamcinolone acetonide intravitreal injection stability
258.
Palonosetron compatibility with lactated Ringer’s, mannitol, and Hextend
injections
259.
Compatibility of some common anti-infective injections with octreotide acetate
260.
Compatibility of various drug inhalation solutions with hypertonic saline
261.
Stability of verteporfin in infusion solutions
262.
Oxybutynin chloride stability prepared for intravesical instillation
263.
Perphenazine stability in two oral liquid vehicles
264.
Compatibility of selected injectable drugs with octreotide acetate
265.
Stability of porfimer sodium in dextrose 5% and in normal saline
266.
Alefacept compatibility with normal saline
267.
Natalizumab stability and compatibility in normal saline
268.
Stability of esomeprazole for oral and enteral administration in common
beverages
269.
Compatibility of selected controlled drugs with octreotide acetate during
simulated Y-site administration
270.
Ibandronate sodium compatibility with infusion solutions
271.
Gabapentin whole and split tablet stability
272.
Fosaprepitant dimeglumine compatibility with infusion solutions
273.
Meropenem decomposition in alkaline media
274.
Compatibility of octreotide acetate with selected penicillins and cephalosporin
antibiotics
275.
Long-term stability of diazepam injection
276.
Artesunate stability in normal saline
277.
Dipyridamole compatibility in infusion solutions
278.
Haloperidol lactate stability after initial opening
279.
Octreotide acetate compatibility with selected common anti-infective drugs
280.
Octreotide acetate compatibility with selected parenteral medications
281.
Compatibility of Voluven (hydroxyethyl starch 6% in NS) with 38 parenteral
drugs
282.
Palifermin stability and incompatibility with heparin
283.
Palonosetron HCl compatibility with five common parenteral drugs
284.
Compatibility of various antineoplastic drugs with octreotide acetate
285.
Stability of insulin aspart and insulin glulisine in ambulatory pumps
286.
Pefloxacin mesylate and ascorbic acid stability and compatibility in D5W
287.
Compatibility and stability of palonosetron with glycopyrrolate and neostigmine
288.
Busulfan stability in syringes
289. Photodestabilization of epinephrine by bisulfite
antioxidant
290.
Compatibility of common parenteral drugs with octreotide acetate
291.
Sunitinib malate stability in an oral liquid formulation
292.
Clofarabine stability in infusion solutions
293.
Ziconotide stability and compatibility with fentanyl and sufentanil
294.
Incompatibility of methylprednisolone with vecuronium and rocuronium
295.
Compatibility of octreotide acetate with several parenteral antineoplastic
drugs
296.
Ibutilide fumarate stability and compatibility in D5W and NS
297.
Nelarabine infusion stability
298.
Tranexamic acid compatibility with drugs and solutions
299.
Artesunate stability in pharmaceutical solvents
300.
Incompatibility of methylprednisolone with diltiazem, ketamine, and midazolam
301.
Compatibility of octreotide acetate with various parenteral drugs
302. Sterile
glycerin preparation sterilization techniques
303.
Abatacept stability in normal saline
304.
Cytarabine compatibility with selected parenteral drugs
305.
Extended stability of naltrexone HCl injection
306.
Levetiracetam injection compatibility and stability
307. The
compatibility of common parenteral anti-infective drugs with cytarabine
injection
308.
Stability of five antibiotics in elastomeric portable pumps under “in use”
conditions.
309.
Stability of insulin during simulated summer and winter shipping conditions
310.
Compatibility of cytarabine with opiates, opioids, and other controlled drugs
311.
Extended stability of tramadol and metoclopramide admixture
312.
Stability of carboprost and misoprostol injections
313.
Compatibility of common injectable drugs with cytarabine
314.
Increased hydrolysis rate of imipenem and aztreonam due to the presence of
metal ions
315.
Stability on Imexon in normal saline
316.
Cytarabine compatibility with beta-lactam antibiotics
317.
Stability and compatibility of fluorouracil and metoclopramide
318.
Extended stability of thiopental sodium in syringes
319.
Compatibility of selected anti-infective injections with cytarabine
320.
Diazepam and lorazepam stability in paramedic vehicles
321.
Acyclovir stability in sodium lactate 1/6 M
322.
Stability of eleven anti-infective agents admixed with magnesium sulfate
323.
Compatibility of some parenteral injections with cytarabine injection
324.
Compatibility of rocuronium bromide with common parenteral medications
325. Infliximab
stability in normal saline
326.
Incompatibility of pefloxacin with aminophylline
327.
Fluticasone compatibility with albuterol and ipratropium
328. The
compatibility of various injections with rocuronium bromide
329.
Bendamustine HCl stability in normal saline
330.
Acetylcysteine flavored oral liquid stability
331.
Incompatibility of promethazine HCl and fluorescein sodium injection
332.
Opiates, opioids, and other controlled drugs' compatibility with rocuronium
bromide
333.
Dexamethasone and ondansetron compatibility in syringes
334.
Metoprolol tartrate stability in D5W and NS
335.
Stability of morphine diluted for use in infants
336.
Stability of vitamins A, D, E, and K in oral capsules
337.
Rocuronium bromide compatibility with selected injections
338.
Stability of sildenafil for pulmonary hypertension in two oral liquid
formulations
339.
Stability of cyclosporine topical hydrogel prepared from oral liquid
340.
Citalopram HCl stability in D5W and Normal Saline
341.
Selected anti-infective drugs compatibility with rocuronium bromide
342,
343. Bendamustine hydrochloride hydrolysis in
aqueous media (2 papers)
344.
Ultraviolet light effects on aztreonam in solution
345.
Rocuronium bromide compatibility with various beta-lactam antibiotics
346.
Dinoprostone stability in a cervical gel formulation
347.
Bortezomib stability in normal saline
348.
Compatibility of selected anti-infective agents with rocuronium bromide
349.
Bendamustine HCl stability in normal saline
350.
Etoposide compatibility with selected parenteral drugs
351.
Palonosetron HCl compatibility and stability with gentamicin, metronidazole,
and vancomycin
352.
Midazolam HCl stability at 5 and 0.5 mg/mL at three temperatures including
frozen
353.
Compatibility of several parenteral drugs with etoposide
354.
Ranitidine HCl stability in unit dose packaging
355.
Hydrocortisone and prednisolone stability in hydrophilic and lipophilic topical
formulations with zinc oxide
356.
Caspofungin acetate compatibility with selected other drugs
357.
Stability of haloperidol and midazolam with other drugs use in infusors
358.
Etoposide compatibility with common drugs given by the intravenous route
359.
Succinylcholine chloride stability at room temperature
360.
Cyclophosphamide and ifosfamide admixed with mesna in LVPs
361.
Compatibility test results of etoposide with other injections
362.
Palonosetron HCl compatibility with 4 neuromuscular blocking drugs
363.
Compatibility of selected controlled drugs with etoposide
364. Mercaptopurine
oral suspension stability
365.
Fluorescein injection incompatibility with neostigmine
366.
Long-term stability of an extemporaneously prepared mixture of epinephrine,
fentanyl, and bupivacaine for epidural administration
367. The
compatibility of selected beta-lactam antibiotics with etoposide
368.
Tramadol HCl injection stability
369.
Etoposide compatibility with common anti-infective injectable medications
370.
Compatibility of selected parenteral drugs with vecuronium bromide
371. Ceftobiprole
medocaril compatibility with 70 drugs in 3 solutions
372.
Cyclosporine topical emulsion instability
373.
Stability of fortified eye drops of amikacin, ceftazidime, and vancomycin
374.
Compatibility of vecuronium bromide with selected anti-cancer drugs
375.
Stability of amphotericin B nasal spray
376.
Extended stability of iobenguane sulfate sterile solution
377. The
compatibility of selected penicillins and cephalosporins with vecuronium
bromide
378.
Compatibility and stability of cefuroxime sodium with ophthalmic solution
additives
379.
Compatibility of vecuronium bromide with other injectable drugs
380.
Fomepizole injection stability in infusion solutions
381. Dornase
alfa incompatibility with albuterol and ipratropium inhalation solutions
382,
383, 384.
Piperacillin sodium stability repackaged in glass and in plastic syringes (3
studies)
385.
Vecuronium bromide compatibility with common parenteral medications
386.
Compatibility of opiates, opioids, and other controlled drugs with vecuronium
bromide
387.
Ketoconazole ophthalmic stability
388.
Cosyntropin stability in solutions
389.
Compatibility of vecuronium bromide with selected anti-infective drugs
390.
Compatibility and stability of pefloxacin mesylate with solutions and selected
drugs
391,
392, 393, 394. Solution stability of azacitidine. (4 studies)
395.
Extended stability of esomeprazole sodium in three infusion solutions
396.
Stability of diamorphine HCl and hyperbaric bupivacaine HCl
397.
Stability and compatibility of anakinra with morphine and ciprofloxacin
398. Effect
of pH on tetracaine stability
399.
Methotrexate compatibility with common injectable drugs
400. Ethanol
stability in polypropylene syringes
401.
Doripenem stability in various infusion solutions
402.
Compatibility of methotrexate with narcotics and other controlled drugs
403.
Caspofungin compatibility with 67 selected other drugs
404.
Dexrazoxane stability in lactated Ringer’s injection
405.
Methotrexate compatibility with penicillin and cephalosporin antibiotics
406.
Ofloxacin stability in infusion solutions
407.
Warfarin sodium stability compounded in an oral liquid formulation
408.
Erythromycin stability in peritoneal dialysis solutions
409. The
compatibility of selected parenteral drugs with methotrexate sodium
410.
Stability of bupivacaine and fentanyl for epidural anesthesia
411.
Stability of propofol and rocuronium admixtures
412.
Mitoxantrone stability in infusion solutions in PVC bags
413.
Compatibility of selected parenteral anti-infective drugs with methotrexate
sodium
414.
Stability of quinine dihydrochloride in infusion solutions
415.
Oseltamivir stability in three oral liquid formulations
416.
Stability of a 1:1 mixture of thiopental and propofol
417.
Decomposed colistimethate inhalation solution toxicity
418.
Stability of colistin and colistimethate in aqueous media
419.
Stability of povidone-iodine at 37 °C
420.
Stability of a captopril oral solution prepared from powder
421.
Stability of diclofenac and piroxicam gel “patches”
422.
Compatibility of methotrexate sodium with selected parenteral medications
423.
Calcitonin salmon pH stability
424. Effect
of sodium chloride on the stability of tetracaine during autoclaving
425.
Tropicamide stability pH dependency
426.
Stability and compatibility of lidocaine HCl with technetium 99m sulfur colloid
427.
Extended stability of diltiazem HCl in D5W and NS
428.
Meperidine HCl compatibility with selected antineoplastic drugs
429.
Stability of compounded codeine phosphate oral liquid
430.
Stability of a bupivacaine and ziconotide admixture for IT administration
431.
Stability and compatibility of a pefloxacin mesylate and vitamin C admixture
432.
Ribavirin injection stability in 3 infusion solutions
433.
Tretinoin stability in five topical formulations
434.
Stability of a ziconotide and clonidine with and without morphine admixtures
435.
Compatibility of cytotoxic drugs with meperidine HCl
436. Benzoyl
peroxide compatibility with other formulation components
437. Stability
and compatibility of somatostatin injection in 5 infusion solutions
438.
Photostability of minoxidil
439.
Baclofen and ziconotide admixtures stability
440.
Omeprazole stability in four infusion solutions
441.
Cysteamine HCL stability in an oral liquid
442.
Ziconotide stability in Synchromed pumps
443.
Compatibility of selected parenteral medications with meperidine HCl
444.
Alemtuzumab stability in infusion solutions
445.
Fluoxetine HCl stability in an oral liquid formulation
446.
Omeprazole oral suspension stability
447.
Stability of levothyroxine and liothyronine injections
448.
Physostigmine sulfate ophthalmic solution stability
449.
Stability of budesonide in topical formulations
450.
Stability of ziconotide acetate diluted in sodium chloride 0.9%
451.
Alendronate sodium sterile dental gel
452.
Meperidine hydrochloride compatibility with selected injectable drugs
453.
Stability of isoetharine, metaproterenol, and terbutaline in respiratory
therapy
454.
Anthralin stability in topical vehicles
455.
Guaifenesin stability in concentrated solutions
456.
Stability of dinoprostone suppositories
457.
Stability of dinoprostone g58el
458.
Retinoic acid eye drops stability
459. Vancomycin
eye drops stability
460. Benzoyl
peroxide solubility and stability in various solvents
461.
Apomorphine solution stability
462.
Compatibility of risperidone and lithium citrate oral liquids